knowledge -WSS

knowledge

author：comprehensive 2025-09-06 04:13:26 - browse：1

ASH19 CAR-T — Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

That sounds staggering to many patients — but it’s far less than analysts expected.

The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

explore

WSS

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

GSK to buy asthma

Profiling embryos to choose those with higher IQs is almost a reality

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Ascension's ugly legal battle over care for poor patients in Texas

Medicare Advantage overpayments discussion gets experts fired up

explore

knowledge

leisure time

The cancer drug shortage isn’t new — and neither are the solutions

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Hollywood unions extend contract negotiations for actors

Study suggests new cause of Down syndrome: cells linked to aging

Medicare details structure of new drug price negotiation program

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

How to save PrEP access — and even expand it

Health and fitness trackers are measuring the wrong things

Walensky prepares to leave CDC — and Congress — behind

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

focus

Idaho abortion case may prompt more restrictions in other states

Idaho abortion case may prompt more restrictions in other states

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Male doctors called my cancer incurable. A female doctor showed it wasn't

American taxpayers paid $1.8 trillion in health care costs in 2022

Nonprofit, backed by Microsoft, to certify AI tools in health care

focus

Wikipedia

explore

hotspot